Dutch biotechnology company Crucell N.V. (Euronext and NASDAQ: CRXL; Swiss Exchange: SW CRX) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with global biopharmaceutical leader UCB S.A. (Euronext: UCB). This agreement allows UCB to evaluate the PER.C6® cell line for research and manufacturing of monoclonal antibodies. Financial details were not disclosed.
